JP2014527397A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527397A5
JP2014527397A5 JP2014516320A JP2014516320A JP2014527397A5 JP 2014527397 A5 JP2014527397 A5 JP 2014527397A5 JP 2014516320 A JP2014516320 A JP 2014516320A JP 2014516320 A JP2014516320 A JP 2014516320A JP 2014527397 A5 JP2014527397 A5 JP 2014527397A5
Authority
JP
Japan
Prior art keywords
chokα
expression level
patient
sample
reference value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014516320A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527397A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/061790 external-priority patent/WO2012175537A1/en
Publication of JP2014527397A publication Critical patent/JP2014527397A/ja
Publication of JP2014527397A5 publication Critical patent/JP2014527397A5/ja
Pending legal-status Critical Current

Links

JP2014516320A 2011-06-20 2012-06-20 癌患者の化学療法に対する臨床応答を予測する方法 Pending JP2014527397A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11382211.8 2011-06-20
EP11382211 2011-06-20
US201161507833P 2011-07-14 2011-07-14
US61/507,833 2011-07-14
EP11382294.4 2011-09-16
EP11382294 2011-09-16
PCT/EP2012/061790 WO2012175537A1 (en) 2011-06-20 2012-06-20 Method for predicting the clinical response to chemotherapy in a subject with cancer

Publications (2)

Publication Number Publication Date
JP2014527397A JP2014527397A (ja) 2014-10-16
JP2014527397A5 true JP2014527397A5 (https=) 2015-08-13

Family

ID=47422050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014516320A Pending JP2014527397A (ja) 2011-06-20 2012-06-20 癌患者の化学療法に対する臨床応答を予測する方法

Country Status (11)

Country Link
US (1) US20150004252A1 (https=)
EP (1) EP2721174A1 (https=)
JP (1) JP2014527397A (https=)
KR (1) KR20140047664A (https=)
CN (1) CN103687964A (https=)
AU (1) AU2012274156A1 (https=)
BR (1) BR112013032857A2 (https=)
CA (1) CA2840129A1 (https=)
MX (1) MX2013015286A (https=)
RU (1) RU2014101492A (https=)
WO (1) WO2012175537A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
US20170305861A1 (en) * 2016-04-25 2017-10-26 Immunomet Therapeutics, Inc Heteroaryl compounds comprising nitrogen and use thereof
US10683292B2 (en) * 2016-07-25 2020-06-16 Nerviano Medical Sciences S.R.L. Purine and 3-deazapurine analogues as choline kinase inhibitors
WO2018177326A1 (en) * 2017-03-29 2018-10-04 Crown Bioscience Inc. (Taicang) System and method for determining karenitecin sensitivity on cancer
CN107050668B (zh) * 2017-06-09 2020-03-31 南京医科大学第一附属医院 基于云处理的放疗效果预测方法
EP3502700A1 (en) * 2017-12-21 2019-06-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods based on the detection of rad51 foci in tumor cells
CN116859058A (zh) * 2023-07-17 2023-10-10 上海中医药大学 一种基于NDR1-Myc互作抗结直肠癌活性分子筛选方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2237332B1 (es) 2004-01-14 2006-11-01 Consejo Sup. Investig. Cientificas Derivados de piridinio y quinolinio.
WO2006108905A1 (es) * 2005-04-13 2006-10-19 Consejo Superior De Investigaciones Científicas Método in vitro para identificar compuestos para terapia del cáncer
GB0519405D0 (en) * 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
RU2509809C2 (ru) * 2008-07-04 2014-03-20 Транслэшионал Кэнсэр Драгз Фарма, С.Л. Способы лечения и диагностики рака
US9896720B2 (en) 2008-09-10 2018-02-20 Rutgers, The State University Of New Jersey Imaging individual mRNA molecules using multiple singly labeled probes
US20100068302A1 (en) 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer

Similar Documents

Publication Publication Date Title
Zhang et al. MicroRNAs: a new key in lung cancer
Yu et al. NEAT 1: A novel cancer‐related long non‐coding RNA
JP2014527397A5 (https=)
Chen et al. Predicting distant metastasis and chemoresistance using plasma miRNAs
Yu et al. The role of mi RNA s in cutaneous squamous cell carcinoma
Drygin et al. Targeting the nucleolus for cancer-specific activation of p53
WO2014172376A3 (en) Markers of tumor cell response to anti-cancer therapy
Yan et al. Expression and significance of circulating microRNA-31 in lung cancer patients
Han et al. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer
Li et al. Clinical significance of blood‑based miRNAs as biomarkers of non‑small cell lung cancer
JP2014533960A5 (https=)
Jing et al. Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target
RU2014101492A (ru) Способ прогнозирования клинического ответа на химиотерапию у субъекта, имеющего рак
ES3014982T3 (en) Novel rna molecule for cancer detection
Bai et al. Establishment of tumor treating fields combined with mild hyperthermia as novel supporting therapy for pancreatic cancer
CN103725779A (zh) 一种非小细胞肺癌早期诊断血清/血浆miRNA标志物及其应用
Robinson et al. The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma
Ondracek et al. Global microRNA expression profiling identifies unique microRNA pattern of radioresistant glioblastoma cells
WO2011153345A3 (en) A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients
Fang et al. The expression of microRNA-340 and cyclin D1 and its relationship with the clinicopathological characteristics and prognosis of lung cancer
Wiemer Prognostic Circulating MicroRNA Biomarkers in Early‐Stage Non‐Small Cell Lung Cancer: A Role for miR‐150
Bałan et al. Disorders noticed during development of pancreatic cancer: potential opportunities for early and effective diagnostics and therapy
EA201501095A1 (ru) Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли
Patil Validation of a nomogram for predicting risk of local recurrence for ductal carcinoma in situ
Huang et al. Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p